0.4128  0.031 (8.06%)		07-26 16:00
Open: 0.38 High: 0.4179 Volume: 309,554		Pre. Close: 0.382 Low: 0.38 Market Cap: 1(M)

Short term
Mid term
Targets	6-month :	0.63	1-year :	0.74
Resists	First :	0.54	Second :	0.63
Pivot price	0.48
Supports	First :	0.37	Second :	0.31
MAs	MA(5) :	0.42	MA(20) :	0.47
	MA(100) :	0.98	MA(250) :	2.26
MACD	MACD :	-0.1	Signal :	-0.1
%K %D	K(14,3) :	8.4	D(3) :	13.4
RSI	RSI(14): 36.1
52-week	High :	8.59	Low :	0.37

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ PRFX ] has closed above bottom band by 17.0%. Bollinger Bands are 47.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	0.42 - 0.42	0.42 - 0.42
Low:	0.37 - 0.38	0.38 - 0.38
Close:	0.41 - 0.41	0.41 - 0.42

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Fri, 26 Jul 2024
PainReform Ltd hits 52-week low, trading at 0.379 USD - Investing.com

Thu, 25 Jul 2024
PRFX - PainReform Ltd. Latest Stock News & Market Updates - StockTitan

Wed, 24 Jul 2024
PainReform files patent for cost-effective drug production - Investing.com

Wed, 24 Jul 2024
PainReform Files Patent Covering Highly Scalable - GlobeNewswire

Tue, 09 Jul 2024
PainReform Announces Crucial Shareholders Meeting - TipRanks

Wed, 26 Jun 2024
PainReform Completes Enrollment in the Second Part of its Phase 3 Bunionectomy Trial for PRF-110 - GlobeNewswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Neutral
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	3 (M)
Shares Float	1 (M)
Held by Insiders	6.2 (%)
Held by Institutions	14.6 (%)
Shares Short	52 (K)
Shares Short P.Month	16 (K)

EPS	-7.74
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	1
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-100.9 %
Return on Equity (ttm)	-233.6 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-3.67
Qtrly Earnings Growth	0 %
Operating Cash Flow	-8 (M)
Levered Free Cash Flow	-4 (M)

PE Ratio	-0.06
PEG Ratio	0
Price to Book value	0.41
Price to Sales	0
Price to Cash Flow	-0.18

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.